Pharmacological Modulation of NLRP3: From Therapy Personalization to Innovative Drugs
Open Access
- 30 October 2025
- journal article
- review article
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (10) , 39537
Abstract
The nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome is a multiprotein complex fundamental for the secretion of pro-inflammatory cytokines during the innate immune response. NLRP3 dysregulation is implicated in the pathogenesis of several diseases, such as inflammatory bowel disease, arthritis, cancer, Alzheimer’s disease, and type 2 diabetes. The pharmacological modulation of NLRP3 by several compounds, which are fully described in this review, represents an important strategy to regulate inflammatory processes. Moreover, NLRP3 is also involved in drug-related adverse reactions, and its pharmacological modulation represents a rapid strategy to mitigate such adverse effects, as reported in this study. NLRP3 inflammasome activation is tightly regulated by post-transcriptional modifications and epigenetic factors, such as long non-coding RNAs (lncRNAs) and DNA methylation, as well as other interacting regulators. Recently, different studies have revealed the importance of NLRP3 levels in predicting drug response. In particular, the methylation of the NLRP3 promoter, which is associated with the inflammasome expression level, emerged as a new promising pharmacoepigenetic biomarker for the glucocorticoid therapy response in several inflammatory disease conditions.Keywords
Funding Information
- Italian Ministry of Health (RC 15/23)
This publication has 124 references indexed in Scilit:
- Posttranslational modifications of NLRP3 and their regulatory roles in inflammasome activationEuropean Journal of Immunology, 2023
- Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patientsInflammation Research, 2023
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)Clinical Pharmacology in Drug Development, 2022
- AS3MT facilitates NLRP3 inflammasome activation by m6A modification during arsenic-induced hepatic insulin resistanceCell Biology and Toxicology, 2022
- Hepatoprotective effect of allicin against acetaminophen‐induced liver injury: Role of inflammasome pathway, apoptosis, and liver regenerationJournal of Biochemical and Molecular Toxicology, 2020
- Carbamazepine promotes specific stimuli-induced NLRP3 inflammasome activation and causes idiosyncratic liver injury in miceArchives of Toxicology, 2019
- Chicoric acid prevents methotrexate-induced kidney injury by suppressing NF-κB/NLRP3 inflammasome activation and up-regulating Nrf2/ARE/HO-1 signalingInflammation Research, 2019
- Stressing out the mitochondria: Mechanistic insights into NLRP3 inflammasome activationJournal of Leukocyte Biology, 2018
- Autophagy inhibition‐enhanced assembly of the NLRP3 inflammasome is associated with cisplatin‐induced acute injury to the liver and kidneys in ratsJournal of Biochemical and Molecular Toxicology, 2018
- MicroRNA‐22 suppresses cell proliferation, migration and invasion in oral squamous cell carcinoma by targeting NLRP3Journal of Cellular Physiology, 2018